Institutional Fund
Versant Venture Management, LLC
San Francisco, CACIK 15600095 filings on record
Portfolio Value
$141.41M
Q1 2026
Holdings
8
Reported positions
New Buys
1
Opened this quarter
QoQ Change
-6.4%
from $151.06M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Monte Rosa Therapeutics Inc37.0%
- Century Therapeutics Inc19.4%
- Lenz Therapeutics Inc17.2%
- Jade Biosciences Inc15.2%
- Contineum Therapeutics Inc5.0%
- Crispr Therapeutics AG5.0%
- Other1.2%
Portfolio Holdings
8 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics Inc | 3.18M | $52.32M | 37.0% | −1.20M | Reduced |
| 2 | Century Therapeutics Inc | 12.17M | $27.50M | 19.4% | +12.17M | New |
| 3 | Lenz Therapeutics Inc | 2.66M | $24.31M | 17.2% | 0 | Held |
| 4 | Jade Biosciences Inc | 1.53M | $21.44M | 15.2% | 0 | Held |
| 5 | Contineum Therapeutics Inc | 542.6K | $7.09M | 5.0% | 0 | Held |
| 6 | Crispr Therapeutics AG | 148.8K | $7.08M | 5.0% | 0 | Held |
| 7 | Skye Bioscience Inc | 2.01M | $1.23M | 0.9% | 0 | Held |
| 8 | Tempest Therapeutics Inc | 269.8K | $442.4K | 0.3% | 0 | Held |